David Ross Parkinson
CIK 1451935 · President and CEO · last filed 2025-10-15
David Ross Parkinson is a President and CEO who has filed 35 SEC Form 4 insider transactions across 7 companies since 2009. Across all open-market trades the lifetime net is +$94.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $26.9K across reported positions. 5 SEC filings were submitted jointly with ABBOTT BIOTHERAPEUTICS CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EPIX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
170 HARBOR WAY SUITE 300
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ESSA Pharma Inc. (EPIX) Delisted | Chief Executive Officer | 65,675 | $0.20 | $13.2K | $94.7K | 6 | 2024-03-28 |
| CTI BIOPHARMA CORP (CTIC) Delisted | Director | — | $9.09 | — | $0 | 8 | 2023-06-26 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | — | — | — | $0 | 3 | 2019-10-04 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 2,849 | — | — | $0 | 5 | 2017-01-05 |
| Molecular Templates, Inc. (THLD) Delisted | Director | — | — | — | $0 | 5 | 2016-06-28 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Director | — | $0.54 | — | $0 | 1 | 2013-05-21 |
| FACT | Director | 2,500 | $10.75 | $26.9K | $0 | 3 | 2010-04-21 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-15 | — | Disp (D) | −65,675 | $0 | |
| 2024-03-28 | ESSA Pharma Inc. (EPIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-18 | ESSA Pharma Inc. (EPIX) Delisted | Buy (P) | +9,223 | $21.2K | EDGAR |
| 2023-06-26 | CTI BIOPHARMA CORP (CTIC) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-04-07 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | ESSA Pharma Inc. (EPIX) Delisted | Buy (P) | +24,434 | $59.0K | EDGAR |
| 2022-11-01 | ESSA Pharma Inc. (EPIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-07-05 | ESSA Pharma Inc. (EPIX) Delisted | Buy (P) | +4,887 | $14.5K | EDGAR |
| 2022-03-11 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-12 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.